Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Deferred Taxes (2016 - 2017)

Aptevo Therapeutics' Deferred Taxes history spans 3 years, with the latest figure at -$7.5 million for Q4 2017.

  • For Q4 2017, Deferred Taxes rose 51.07% year-over-year to -$7.5 million; the TTM value through Dec 2017 reached -$23.3 million, down 47.28%, while the annual FY2017 figure was -$2000.0, 99.99% up from the prior year.
  • Deferred Taxes for Q4 2017 was -$7.5 million at Aptevo Therapeutics, up from -$15.3 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at -$11000.0 in Q2 2016 and bottomed at -$15.3 million in Q4 2016.
  • The 3-year median for Deferred Taxes is -$575000.0 (2015), against an average of -$4.0 million.
  • The largest annual shift saw Deferred Taxes crashed 2195.5% in 2016 before it surged 51.07% in 2017.
  • A 3-year view of Deferred Taxes shows it stood at -$667000.0 in 2015, then plummeted by 2195.5% to -$15.3 million in 2016, then soared by 51.07% to -$7.5 million in 2017.
  • Per Business Quant, the three most recent readings for APVO's Deferred Taxes are -$7.5 million (Q4 2017), -$15.3 million (Q4 2016), and -$483000.0 (Q3 2016).